
Neurogene Inc (NGNE) Stock Forecast & Price Target
Neurogene Inc (NGNE) Analyst Ratings
Bulls say
Neurogene is a promising biotechnology company with a differentiated product portfolio targeting rare neurological diseases through its proprietary transgene regulation technology, EXACT. Their clinical data for NGN-401 in the treatment of Rett syndrome and NGN-101 for CLN5 Batten disease have shown promising results and emboldened our confidence in their ability to successfully develop these treatments. While there are inherent risks in the biotech industry, we believe Neurogene's execution and continued focus on innovative treatments will result in strong product revenue growth in the future.
Bears say
Neurogene is a clinical-stage biotechnology company with a focus on developing genetic medicines for rare neurological diseases through its proprietary EXACT platform. Its latest drug candidates NGN-401 and NGN-101 show potential in treating Rett syndrome and CLN5 Batten disease, respectively. With a recent financing of $135 million and ongoing PPQ campaign, the company's cash runway is extended into 2029. The longer-term data of NGN-401 positions it as a potential competitor to TSHA, and the analyst has raised the price target to $81. However, concerns remain about the delay in the Ph 1/2 data presentation and the company's future profitability.
This aggregate rating is based on analysts' research of Neurogene Inc and is not a guaranteed prediction by Public.com or investment advice.
Neurogene Inc (NGNE) Analyst Forecast & Price Prediction
Start investing in Neurogene Inc (NGNE)
Order type
Buy in
Order amount
Est. shares
0 shares